Merck has acquired, through a subsidiary, OncoEthix, a Swiss-based privately held biotechnology company specializing in oncology drug development. Through the acquisition, Merck has gained an investigational, novel oral BET inhibitor, OTX015, which is currently in Phase 1b studies for the treatment of hematological malignancies and advanced solid tumors.
A wave of corporate mega deal activity drove a significant uptick in M&A value in 2014,...
Walgreens announced that Greg Wasson, president and chief executive officer, has informed the...
The debt-financed acquisition of Cubist Pharmaceuticals by Merck for $9.5 billion is the latest in a string of large, debt-financed acquisitions that are stressing the credit profiles of US healthcare companies, according to Fitch Ratings.
Natrol has announced the completion of the sale of substantially all of the company’s assets to Aurobindo Pharma USA Inc., a manufacturer of generic pharmaceuticals and active pharmaceutical ingredients, for a purchase price of $132.5M plus assumed liabilities.
Sigma-Aldrich Corporation stockholders voted to adopt the previously announced merger agreement providing for the acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany at a special meeting of stockholders.
Merck is buying Cubist Pharmaceuticals for $8.4 billion, illustrating a new emphasis on combating so-called "superbugs" that are drawing dire warnings from global health organizations.
Noble Life Sciences, a provider of preclinical drug development services, has announced the acquisition of Spring Valley Laboratories, a full service, GLP-compliant, preclinical contract research organization for the development of drugs, vaccines, and medical devices.
According to a survey by KPMG LLP, merger and acquisition (M&A) activity is reemerging as a leading growth strategy among U.S.organizations for 2015. Of the 738 M&A professionals, investors and advisors who participated in the survey, 82 percent anticipate that their U.S. companies or clients will initiate at least one acquisition in 2015, compared with 63 percent in 2014.
Johnson Matthey, a provider of pharmaceutical services, APIs and catalyst technologies, has announced completion of an acquisition of pharmaceutical manufacturing capacity in Scotland, U.K. The 109,000 sq. meter site was acquired to meet increasing demand for custom pharmaceutical services and active ingredients utilising enhanced manufacturing capabilities.
Imprimis Pharmaceuticals has entered into a stock purchase agreement to acquire South Coast Specialty Compounding, Inc., DBA Park Compounding (Park). The acquisition of Park is expected to close on or about January 1, 2015, subject to the satisfaction of certain customary closing conditions.
Otsuka Pharmaceutical will spend $3.5 billion in cash to buy Avanir Pharmaceuticals in a deal that expands the Japanese drugmaker's portfolio of neurologic disease treatments. Avanir shareholders will receive $17 per share, according to the agreement announced Tuesday.
Pfizer has completed the acquisition of Baxter International Inc.’s portfolio of marketed vaccines. The portfolio that was acquired consists of NeisVac-C and FSME-IMMUN/TicoVac. Pfizer also acquired a portion of Baxter’s facility in Orth, Austria, where these vaccines are manufactured.
Cocrystal Pharma, a biotechnology company developing novel antiviral therapeutics for human diseases, today announced the closing of its merger with RFS Pharma, a privately owned biotech company founded by renowned drug developer, Dr. Raymond Schinazi.
In a big year for deal making, the health care industry is a standout. Large drugmakers are buying and selling businesses to control costs and deploy surplus cash. A rising stock market, tax strategies and low interest rates are also fueling the mergers and acquisitions.
BioMarin Pharmaceutical will pay $680 million in cash for the Dutch biotech company Prosensa in a bid to strengthen its pipeline of genetic disorder treatments.
Apellis Pharmaceuticals has entered into an agreement to acquire Potentia Pharmaceuticals. As part of the acquisition agreement, Apellis obtained the necessary intellectual property rights to develop its complement inhibitor drug compound (APL-2) in ophthalmology and plans its first clinical trial in dry age-related macular degeneration.
According to Joshua Owide, GlobalData’s Director of Healthcare Industry Dynamics, "The integration of Allergan and Forest will help grow Actavis to a $22 billion healthcare company in 2015. This is a dramatic elevation from its $8.7 billion revenues recorded in 2013, the year in which Actavis completed the $5 billion acquisition of Warner Chilcott."
Actavis will pay $66 billion to buy fellow drugmaker Allergan in a deal that could finally stop a months-long takeover push from Valeant Pharmaceuticals for the Botox maker.
Shares of Allergan jumped in premarket trading Monday after several reports surfaced over the weekend that specialty drugmaker Actavis was preparing to buy the maker of Botox, which is embroiled in a takeover battle with Valeant Pharmaceuticals.
Zoetis Inc. said Friday that it has adopted a one-year shareholder rights plan. These plans, often known as "poison pills", are intended to fight off hostile takeovers. Zoetis said the plan would enable existing shareholders a right to buy preferred stock if a person or group acquires at least 15 percent of the company's stock and tries to buy more.
Activist investor William Ackman has taken a roughly $2 billion stake in Zoetis and could push the animal-health company to sell itself to a larger drug maker.
Golden Gate Capital today announced that it has entered into a definitive agreement to acquire ANGUS Chemical Company from The Dow Chemical Company for $1.215 billion.
Allergan today announced that its Board of Directors has approved amendments to the company’s bylaws that streamline the process associated with calling a special meeting of stockholders. The Board determined to amend the bylaws after meetings with many of the Company’s major stockholders and other governance organizations to solicit their input and perspectives.
Eurofins Scientific has announced the pending acquisition of SF Analytical (SFA) Laboratories. The transaction will close at the end of November. The acquisition strengthens Eurofins' growing presence in the US, as well as expands the current base of operations in the Midwestern United States.
Perrigo Company and Omega have entered into a definitive agreement in which Perrigo has agreed to acquire Omega for EUR3.6 billion, or $4.5 billion, comprised of the purchase of Omega's equity for EUR2.48 billion and the assumption of EUR1.1 billion in debt.
GVK BIO has announced the signing of a definitive agreement to acquire Vanta Bioscience, a full service preclinical GLP toxicology and safety assessment contract research organization operating out of Chennai, India.
In a win for Valeant and Pershing Square, a federal judge has decided that they can vote in takeover target Allergan's upcoming shareholder meeting. Allergan said in a statement Tuesday that it will file an emergency appeal.
- Page 1